New Focus by NCI’s CPTC Targets Vendors to Bring Deliverables to Research Community | GenomeWeb
CAMBRIDGE, Mass. — With its technology-development programs well under way, the National Cancer Institute’s Clinical Proteomic Technologies for Cancer initiative has begun turning its attention to the big vendor community.
 
Its aim is to get those companies tools into the research community and to invest big commercial players more heavily into CPTC’s efforts, its director, Henry Rodriguez, told ProteoMonitor this week.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.